APGE Stock Summary and Trading Ideas (Apogee Therapeutics | NASDAQ:APGE)

Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Apogee Therapeutics trades on the NASDAQ stock market under the symbol APGE.

As of May 12, 2026, APGE stock price declined to $82.93 with 479,662 million shares trading.

APGE has a beta of 0.38, meaning it tends to be less sensitive to market movements. APGE has a correlation of 0.01 to the broad based SPY ETF.

APGE has a market cap of $6.25 billion. This is considered a Mid Cap stock.

The top ETF exchange traded funds that APGE belongs to (by Net Assets): VTI, XBI, IWM, TCAF, VXF.

APGE has outperformed the market in the last year with a return of +122.4%, while the SPY ETF gained +32.1%. In the last 3 month period, APGE beat the market returning +26.0%, while SPY returned +6.9%. However, in the most recent 2 weeks APGE has underperformed the stock market by returning -4.1%, while SPY returned +3.2%.

APGE support price is $82.35 and resistance is $86.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APGE shares will trade within this expected range on the day.